ClinicalTrials.gg
TerminatedNCT00312221Updated Sep 10, 2012Results posted

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis Pain

A Phase 3 interventional study of Buprenorphine and Buprenorphine in Osteoarthritis, sponsored by Purdue Pharma LP. Terminated at 23 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2012-09-10.

Sponsored by Purdue Pharma LP (part of Knoa Pharma) · Phase 3, Interventional, and Treatment

Why this study was terminated
terminated early for administrative reasons unrelated to safety or efficacy

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
418
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 19 studies testing buprenorphine in Osteoarthritis — none open to participants now, none under way, none of them phase 3. Buprenorphine · Osteoarthritis.

Enrollment
2nd of 19
418 · median 196
Started
2004
with 2 others
Phase 3
11 of 19
none open now
Registered
1st of 19
by date
Lead sponsor
9 of 19
Purdue Pharma LP

Among the 19 studies testing buprenorphine in Osteoarthritis, this one is the 2nd largest by enrollment, is one of 3 that started in 2004, is one of 11 in phase 3, and was the 1st registered.

Osteoarthritis

2,977 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

None of the 19 studies testing buprenorphine in Osteoarthritis is open now. The open studies under Osteoarthritis, anywhere →

About buprenorphine

Buprenorphine: first FDA approval 1981 (BUPRENEX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing buprenorphine in Osteoarthritis as a file.
02

Study summary

The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (20 mg) in comparison to the buprenorphine transdermal system (5 mg) and oxycodone immediate release in subjects with moderate to severe osteoarthritis pain currently treated with oral opioids. The double-blind treatment intervention duration is 12 weeks during which time supplemental analgesic medication (acetaminophen, ibuprofen, immediate release oxycodone) will be provided to all subjects in addition to study drug.

Read the detailed description

Buprenorphine is a synthetic opioid analgesic with over twenty-five years of international clinical experience indicating it to be safe and effective in a variety of therapeutic situations for the relief of moderate to severe pain.

03

Conditions studied

  • Osteoarthritis

Browse trials for

Keywords

  • Osteoarthritis, opioid, transdermal
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Osteoarthritis of the hip, knee, or spine for 1 year or longer, confirmed by radiographic evidence within the last 2 years.
  • Good pain control while on a stable dose of an opioid analgesic for osteoarthritis.

Exclusion criteria

Exclusion Criteria:

  • Not currently taking and tolerating opioids.
  • Taking more than 80 mg per day of oral morphine sulfate or equivalent within 30 days of enrollment.
  • Requiring frequent analgesic therapy for chronic condition(s), in addition to osteoarthritis.

Other protocol-specific exclusion/inclusion criteria may apply.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
418 participants (actual)

Study arms

  • Active comparator
    BTDS 5

    Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear

    Drug: Buprenorphine

  • Experimental
    BTDS 20

    Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear

    Drug: Buprenorphine

  • Experimental
    Oxycodone Immediate-Release (Oxy IR) 40 mg

    Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).

    Drug: oxycodone immediate-release

Interventions

  • Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear

    Also known as: Butrans™

  • Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear

    Also known as: Butrans™

  • Drugoxycodone immediate-release

    Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).

06

What researchers measure

Primary outcomes

  1. "Average Pain Over the Last 24 Hours" Scores at Weeks 4, 8, and 12 of the Double-blind Phase.

    The "average pain over the last 24 hours" score was collected using an 11-point numerical scale ranging from 0 to 10, where 0 = no pain and 10 = pain as bad as you can imagine. This variable was obtained at each clinic visit during the double-blind phase of the study (postrandomization weeks 1, 2, 4, 8, and 12).

    Time frame: Weeks 4, 8, and 12 of the double-blind phase

Secondary outcomes

  1. The Mean Daily Number of Supplemental Analgesic Medication Tablets

    The mean daily number of supplemental analgesic medication tablets included sponsor-supplied ibuprofen, acetaminophen, or OxyIR®.

    Time frame: Double-blind phase (84 days)

  2. The Physical Function Subscale of The Western Ontario and McMaster's Universities Osteoarthritis (WOMAC OA) Index at Weeks 4, 8, and 12 of the Double Blind Phase

    The WOMAC (Version LK 3.1) measures symptoms and physical functioning of patients with OA of the hip and knee. It contains 24 items (5 pain, 2 stiffness, 17 physical function) and takes less than 5 minutes to complete. The WOMAC physical function subscale has 17 items coded as 0 to 4 (best to worst), which are summed, giving a range of 0 to 68 (best to worst).

    Time frame: Weeks 4, 8 and 12 of the double-blind phase

  3. The Sleep Disturbance Subscale in The Medical Outcomes (MOS)-Sleep Scale at Weeks 4, 8, and 12 of the Double-blind Phase

    The MOS-Sleep Scale consists of 12 individual items: (4 sleep disturbance, 2 sleep adequacy, 1 quantity of optimal sleep, 3 somnolence, 1 snoring, and 1 shortness of breath) and takes 5 to 10 minutes to complete. Question 1 is scored on a scale of 1 to 5 and Questions 2 to 12 are scored on a scale of 1 to 6. The Sleep Disturbance Subscale score is derived from the scores to Questions 1, 3, 7 and 8, and ranges from 0 to 100, where higher scores indicate greater sleep disturbance.

    Time frame: Weeks 4, 8, and 12 of the Double-blind Phase

07

Results

Posted Sep 15, 2010
Limitations and caveats
This study was terminated early for administrative reasons not related to safety or efficacy. Low enrollment at termination led to reduced power.

Participant flow

Study Dates: 02-Apr-2004 (first subject first visit) to 18 Jul-2005 (last subject last visit); 15-Jun-2005 (first site notified of study termination). The study took place in 82 medical/research sites in the US; 59 sites randomized at least 1 subject.

Open-label Run-in Period
Participant flow — Open-label Run-in Period
MilestoneRun-in PeriodDouble-blind BTDS 5Double-blind BTDS 20Double-blind Oxycodone Immediate-Release
Started652000
Completed418000
Not completed234000
Withdrew: Withdrawal by subject6000
Withdrew: Adverse event74000
Withdrew: Lost to follow-up5000
Withdrew: Administrative42000
Withdrew: Lack of efficacy102000
Withdrew: Did not qualify5000
Double-blind Phase
Participant flow — Double-blind Phase
MilestoneRun-in PeriodDouble-blind BTDS 5Double-blind BTDS 20Double-blind Oxycodone Immediate-Release
Started0136149133
Completed0777763
Not completed0597270
Withdrew: Withdrawal by subject0687
Withdrew: Adverse event0101918
Withdrew: Lost to follow-up0022
Withdrew: Administrative0263733
Withdrew: Lack of efficacy017610

Outcome measures

Primary"Average Pain Over the Last 24 Hours" Scores at Weeks 4, 8, and 12 of the Double-blind Phase.

The "average pain over the last 24 hours" score was collected using an 11-point numerical scale ranging from 0 to 10, where 0 = no pain and 10 = pain as bad as you can imagine. This variable was obtained at each clinic visit during the double-blind phase of the study (postrandomization weeks 1, 2, 4, 8, and 12).

Time frame:
Weeks 4, 8, and 12 of the double-blind phase
Reported as:
Mean · Units on a scale
"Average Pain Over the Last 24 Hours" Scores at Weeks 4, 8, and 12 of the Double-blind Phase.
Units on a scaleDouble-blind BTDS 5Double-blind BTDS 20Double-blind Oxycodone Immediate-Release
Screening6.60 ± 0.1166.58 ± 0.1036.44 ± 0.117
Prerandomization3.25 ± 0.1143.02 ± 0.0933.03 ± 0.099
Week 44.21 ± 0.2193.57 ± 0.1953.45 ± 0.209
Week 83.78 ± 0.2393.37 ± 0.1903.59 ± 0.217
Week 123.67 ± 0.2463.56 ± 0.2303.37 ± 0.232
Statistical analysis
  • Double-blind BTDS 5 vs Double-blind BTDS 20 · Mixed Models Analysis · p = 0.126 · Mean difference (final values): -0.38 · 95% CI -0.8562 to 0.1054Treatment comparison between BTDS 20 and BTDS 5 during the 12-week double-blind phase
  • Double-blind BTDS 5 vs Double-blind Oxycodone Immediate-Release · Mixed Models Analysis · p = 0.140 · Mean difference (final values): -0.36 · 95% CI -0.8455 to 0.1189Treatment comparison between BTDS 5 and oxycodone immediate-release during the 12-week double-blind phase.
SecondaryThe Mean Daily Number of Supplemental Analgesic Medication Tablets

The mean daily number of supplemental analgesic medication tablets included sponsor-supplied ibuprofen, acetaminophen, or OxyIR®.

Time frame:
Double-blind phase (84 days)
Reported as:
Mean · Tablets
The Mean Daily Number of Supplemental Analgesic Medication Tablets
TabletsDouble-blind BTDS 5Double-blind BTDS 20Double-blind Oxycodone Immediate-Release
Prerandomization2.0 ± 0.191.7 ± 0.131.6 ± 0.13
Double-blind3.3 ± 0.262.3 ± 0.192.3 ± 0.22
Statistical analysis
  • Double-blind BTDS 5 vs Double-blind BTDS 20 · ANCOVA · p = 0.007 · Mean difference (final values): -0.8 · 95% CI -1.47 to -0.20Treatment comparison between BTDS 5 and BTDS 20 during the 12-week double-blind phase.
  • Double-blind BTDS 5 vs Double-blind Oxycodone Immediate-Release · ANCOVA · p = 0.011 · Mean difference (final values): -0.8 · 95% CI -1.47 to -0.17Treatment comparison between BTDS 5 and oxycodone immediate-release during the 12-week double-blind phase.
SecondaryThe Physical Function Subscale of The Western Ontario and McMaster's Universities Osteoarthritis (WOMAC OA) Index at Weeks 4, 8, and 12 of the Double Blind Phase

The WOMAC (Version LK 3.1) measures symptoms and physical functioning of patients with OA of the hip and knee. It contains 24 items (5 pain, 2 stiffness, 17 physical function) and takes less than 5 minutes to complete. The WOMAC physical function subscale has 17 items coded as 0 to 4 (best to worst), which are summed, giving a range of 0 to 68 (best to worst).

Time frame:
Weeks 4, 8 and 12 of the double-blind phase
Reported as:
Mean · Units on a scale
The Physical Function Subscale of The Western Ontario and McMaster's Universities Osteoarthritis (WOMAC OA) Index at Weeks 4, 8, and 12 of the Double Blind Phase
Units on a scaleDouble-blind BTDS 5Double-blind BTDS 20Double-blind Oxycodone Immediate-Release
Screening36.88 ± 1.09337.69 ± 0.93036.81 ± 1.043
Prerandomization25.96 ± 0.99324.19 ± 0.94724.42 ± 0.930
Week 430.60 ± 1.18728.34 ± 1.02526.65 ± 1.253
Week 828.70 ± 1.36428.34 ± 1.19926.59 ± 1.405
Week 1229.68 ± 1.50029.35 ± 1.25327.25 ± 1.651
Statistical analysis
  • Double-blind BTDS 5 vs Double-blind BTDS 20 · Mixed Models Analysis · p = 0.707 · Mean difference (final values): -0.48 · 95% CI -3.0054 to 2.0397Treatment comparison between BTDS 5 and BTDS 20 during the 12-week double-blind phase.
  • Double-blind BTDS 5 vs Double-blind Oxycodone Immediate-Release · Mixed Models Analysis · p = 0.187 · Mean difference (final values): -1.79 · 95% CI -4.4459 to 0.8706Treatment comparison between BTDS 5 and oxycodone immediate-release during the 12-week double-blind phase.
SecondaryThe Sleep Disturbance Subscale in The Medical Outcomes (MOS)-Sleep Scale at Weeks 4, 8, and 12 of the Double-blind Phase

The MOS-Sleep Scale consists of 12 individual items: (4 sleep disturbance, 2 sleep adequacy, 1 quantity of optimal sleep, 3 somnolence, 1 snoring, and 1 shortness of breath) and takes 5 to 10 minutes to complete. Question 1 is scored on a scale of 1 to 5 and Questions 2 to 12 are scored on a scale of 1 to 6. The Sleep Disturbance Subscale score is derived from the scores to Questions 1, 3, 7 and 8, and ranges from 0 to 100, where higher scores indicate greater sleep disturbance.

Time frame:
Weeks 4, 8, and 12 of the Double-blind Phase
Reported as:
Mean · Units on a scale
The Sleep Disturbance Subscale in The Medical Outcomes (MOS)-Sleep Scale at Weeks 4, 8, and 12 of the Double-blind Phase
Units on a scaleDouble-blind BTDS 5Double-blind BTDS 20Double-blind Oxycodone Immediate-Release
Screening51.91 ± 2.13955.28 ± 2.03555.74 ± 2.197
Prerandomization34.64 ± 1.95028.65 ± 1.78233.03 ± 1.926
Week 439.23 ± 2.14432.40 ± 1.94135.72 ± 2.298
Week 835.95 ± 2.79131.71 ± 2.47334.13 ± 2.746
Week 1239.13 ± 3.08932.95 ± 2.81936.32 ± 3.290
Statistical analysis
  • Double-blind BTDS 5 vs Double-blind BTDS 20 · Mixed Models Analysis · p = 0.685 · Mean difference (final values): -0.96 · 95% CI -5.6177 to 3.6930Treatment comparison between BTDS 5 and BTDS 20 during the 12-week double-blind phase.
  • Double-blind BTDS 5 vs Double-blind Oxycodone Immediate-Release · Mixed Models Analysis · p = 0.443 · Mean difference (final values): -1.81 · 95% CI -6.4415 to 2.8255Treatment comparison between BTDS 5 and oxycodone immediate-release during the 12-week double-blind phase.

Adverse events

Collected over Adverse Events (AEs) occurring after the signing of informed consent up to study completion or discontinuation; during 7 days after last visit; serious AEs up to 30 days following the last study visit were followed until the event resolved.. Non-serious events are listed at a 4.50% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-blind BTDS 5—3/136 (2.2%)30/136 (22.1%)
Double-blind BTDS 20—7/149 (4.7%)70/149 (47%)
Double-blind Oxycodone Immediate-Release—7/133 (5.3%)56/133 (42.1%)
Run-in, Open-label BTDS 10 and 20—8/652 (1.2%)187/652 (28.7%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventDouble-blind BTDS 5Double-blind BTDS 20Double-blind Oxycodone Immediate-ReleaseRun-in, Open-label BTDS 10 and 20
Acute abdomenGastrointestinal disorders0/1360/1491/1330/652
Acute renal failureRenal and urinary disorders0/1360/1491/1330/652
Acute cholecystitisHepatobiliary disorders0/1360/1491/1330/652
DehydrationMetabolism and nutrition disorders0/1360/1491/1330/652
DiarrheaGastrointestinal disorders0/1360/1491/1330/652
FellGeneral disorders0/1360/1491/1330/652
Fractured left hipInjury, poisoning and procedural complications0/1360/1491/1330/652
GI bleedingGastrointestinal disorders0/1360/1491/1330/652
Recurrent L4-L5 disc herniationMusculoskeletal and connective tissue disorders0/1360/1491/1330/652
Recurrent L5-S1 disc herniation with impingement of the S1 nerve rootNervous system disorders0/1360/1491/1330/652
Most frequent other events
Showing 10 of 15
Most frequent other events
EventDouble-blind BTDS 5Double-blind BTDS 20Double-blind Oxycodone Immediate-ReleaseRun-in, Open-label BTDS 10 and 20
Application site pruritusGeneral disorders13/13622/14912/13347/652
HeadacheNervous system disorders10/13622/14916/13370/652
NauseaGastrointestinal disorders4/13616/14917/13394/652
Application site erythemaGeneral disorders9/13614/1495/1339/652
SomnolenceNervous system disorders2/1362/14910/13329/652
ConstipationGastrointestinal disorders3/1368/1499/13322/652
DizzinessNervous system disorders4/13610/1497/13343/652
Application site rashGeneral disorders5/1369/1498/1339/652
ArthralgiaMusculoskeletal and connective tissue disorders5/1369/1494/13312/652
Upper respiratory tract infection NOSInfections and infestations6/1366/1498/1335/652

Baseline characteristics

Age Continuous
Age Continuous(years)Double-blind BTDS 5Double-blind BTDS 20Double-blind Oxycodone Immediate-ReleaseTotal
Mean58.7 ± 10.7157.9 ± 9.4558.1 ± 10.3658.3 ± 10.15
Sex: Female, Male
Sex: Female, Male(Participants)Double-blind BTDS 5Double-blind BTDS 20Double-blind Oxycodone Immediate-ReleaseTotal
Female10111694311
Male353339107
08

Study locations

23 sites
  • Parkway Medical Center
    Birmingham, Alabama 35215, United States
  • International Clinical Research Network
    Chula Vista, California 91910, United States
  • Clinical Trials Research
    Roseville, California 95661, United States
  • Accelovance
    San Diego, California 92108, United States
  • Torrance Clinical Research
    Torrance, California 90505, United States
  • Southern Colorado Clinic
    Pueblo, Colorado 81008, United States
  • Drug Study Institute
    Jupiter, Florida 33458, United States
  • Innovative Research of West Florida, Inc.
    Largo, Florida 33770, United States
  • International Medical Research
    Ormond Beach, Florida 32174, United States
  • Peninsula Research, Inc.
    Ormond Beach, Florida 32174, United States
  • Palm Beach Research Center
    West Palm Beach, Florida 33409, United States
  • Georgia Medical Research Institute
    Marietta, Georgia 30060, United States
  • Non- Surgical Orthopedic & Spine Center, P.C.
    Marietta, Georgia 30060, United States
  • The Arthritis Center
    Springfield, Illinois 62704, United States
  • Commonwealth Biomedical Research, LLC
    Madisonville, Kentucky 42431, United States
  • Miray Medical Center
    Brockton, Massachusetts 23010, United States
  • Professional Clinical Research Crystal Lake Health Center
    Benzonia, Michigan 49616, United States
  • Rheumatology PC
    Kalamazoo, Michigan 49009, United States
  • Pharm Quest
    Greensboro, North Carolina 27401, United States
  • The Clinical Trial Center, LLC
    Jenkintown, Pennsylvania 19046, United States
  • Amarillo Center for Clinical Research
    Amarillo, Texas 79124, United States
  • Med Search Professional Group/Pharmaceutical C-Trials Inc.
    Hurst, Texas 76054, United States
  • Texas Medical Research Associates
    San Antonio, Texas 78238, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2004, a primary completion of Jul 2005 and a completion of Aug 2005. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2010, 5 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2006
First posted
Apr 7, 2006
Start
Apr 2004
Primary completionActual
Jul 2005
CompletionActual
Aug 2005
Results first posted
Sep 15, 2010
Last update
Sep 10, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00312221
Lead sponsor
Purdue Pharma LP
Responsible party
Sponsor
First posted
Apr 7, 2006
Start date
Apr 2004
Primary completion
Jul 2005
Completion
Aug 2005
Results posted
Sep 15, 2010
Last update
Sep 10, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Buprenorphine

Start the discussion